Intensive Care Patients from the First COVID-19 Wave: One-Year Survival after Tocilizumab Treatment
Introduction: An infection by COVID-19 triggers a dangerous cytokine storm, so tocilizumab has been introduced in Italy as an agent blocking the cytokine storm. This paper aims to describe the one-year survival of ICU patients treated with tocilizumab. Methods: This observational study enrolled all...
Guardado en:
Autores principales: | Gabriele Melegari, Enrico Giuliani, Chiara Dallai, Lucia Veronesi, Elisabetta Bertellini, Suela Osmenaj, Alberto Barbieri |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/60a55ff4f2da4522a9a232afed5a43c3 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Post-COVID-19 Sydrome and Decrease in Health-Related Quality of Life in Kidney Transplant Recipients after SARS-COV-2 Infection—A Cohort Longitudinal Study from the North of Poland
por: Agnieszka Malinowska, et al.
Publicado: (2021) -
Effectiveness of Tocilizumab with and without Dexamethasone in Patients with Severe COVID-19: A Retrospective Study
por: Zarębska-Michaluk D, et al.
Publicado: (2021) -
Major predictive risk factors for а cytokine storm in COVID-19 patients (a retrospective clinical trials)
por: Anna Yu. Anisenkova, et al.
Publicado: (2021) -
Pentoxifylline as a Potential Adjuvant Therapy for COVID-19: Impeding the Burden of the Cytokine Storm
por: Wiktoria Feret, et al.
Publicado: (2021) -
Can Dietary Fatty Acids Affect the COVID-19 Infection Outcome in Vulnerable Populations?
por: J. C. Onishi, et al.
Publicado: (2020)